ConductScience.org, home

Paper39680452

SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts.

Goedeke L and 22 others. J Clin Invest, 2024. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Papers, record 39680452. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39680452

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts.
PubMed
Journal
J Clin Invest
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
7.07, provisional
iCite
Revised in PubMed
2026-07-03
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Goedeke LLeigh
2Ma YYina
3Gaspar RCRafael C
4Nasiri AAli
5Lee JJieun
6Zhang DDongyan
7Galsgaard KDKatrine Douglas
8Hu XXiaoyue
9Zhang JJiasheng
10Guerrera NNicole
11Li XXiruo
12LaMoia TTraci
13Hubbard BTBrandon T
14Haedersdal SSofie
15Wu XXiaohong
16Stack JJohn
17Dufour SSylvie
18Butrico GMGina Marie
19Kahn MMario
20Perry RJRachel J

Source PubMed

See all 23 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Heart FailureMajor topic
Oxidation-ReductionMajor topic
GlucosidesMajor topic
Benzhydryl CompoundsMajor topic
Mitochondria, HeartMajor topic
Animals
Rats
Male
Rats, Sprague-Dawley
Fatty Acids
Myocardium
Pyruvic Acid
Sodium-Glucose Transporter 2
Ketones

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 DK007356NIDDK NIH HHSUnited StatesT32DK007356PubMedNIH RePORTER
UL1 TR001863NCATS NIH HHSUnited StatesUL1TR001863PubMedNIH RePORTER
R01 HL148008NHLBI NIH HHSUnited StatesR01HL148008PubMed and NIHNIH RePORTER
U2C DK134901NIDDK NIH HHSUnited StatesU2CDK134901PubMed and NIHNIH RePORTER
R01 DK119968NIDDK NIH HHSUnited StatesR01DK119968PubMed and NIHNIH RePORTER
P30 DK045735NIDDK NIH HHSUnited StatesP30DK045735PubMed and NIHNIH RePORTER
R00 HL150234NHLBI NIH HHSUnited StatesR00HL150234PubMed and NIHNIH RePORTER

Download CSV of grants

References91

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139041214SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice.Circ Res2024https://conductscience.org/library/papers/39041214PubMed
231196815Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.Lancet Diabetes Endocrinol2019https://conductscience.org/library/papers/31196815PubMed
330106622Cardiac branched-chain amino acid oxidation is reduced during insulin resistance in the heart.Am J Physiol Endocrinol Metab2018https://conductscience.org/library/papers/30106622PubMed
43894678Inhibitory effects of the D(-)isomer of 3-hydroxybutyrate on cardiac non-esterified fatty acid uptake and oxygen demand induced by norepinephrine in the intact dog.J Mol Cell Cardiol1985https://conductscience.org/library/papers/3894678PubMed
535624663Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2/AMPK Pathway.Antioxidants (Basel)2022https://conductscience.org/library/papers/35624663PubMed
69462419Myocardial infarction with aortic banding. A combined rat model of heart failure.Jpn Heart J1997https://conductscience.org/library/papers/9462419PubMed
715314686AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.J Clin Invest2004https://conductscience.org/library/papers/15314686PubMed
826819376The Failing Heart Relies on Ketone Bodies as a Fuel.Circulation2016https://conductscience.org/library/papers/26819376PubMed
912147544Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure.Circulation2002https://conductscience.org/library/papers/12147544PubMed
1030895697
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Eur J Heart Fail2019https://conductscience.org/library/papers/30895697PubMed
1123258802Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart.Eur J Heart Fail2013https://conductscience.org/library/papers/23258802PubMed
1230668551The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.JCI Insight2019https://conductscience.org/library/papers/30668551PubMed
1338118414Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.Cell Rep Med2023https://conductscience.org/library/papers/38118414PubMed
1426819374Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure.Circulation2016https://conductscience.org/library/papers/26819374PubMed
1536223763Extra-cardiac BCAA catabolism lowers blood pressure and protects from heart failure.Cell Metab2022https://conductscience.org/library/papers/36223763PubMed
162058715Effects of beta-hydroxybutyrate on oxidative metabolism and phosphorylation potential in canine heart in vivo.Am J Physiol1991https://conductscience.org/library/papers/2058715PubMed
1725311547Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure.Clin Exp Pharmacol Physiol2015https://conductscience.org/library/papers/25311547PubMed
1833983836Cardiac Energy Metabolism in Heart Failure.Circ Res2021https://conductscience.org/library/papers/33983836PubMed
1924657720Mitochondrial reactive oxygen species production and elimination.J Mol Cell Cardiol2014https://conductscience.org/library/papers/24657720PubMed
2023861485Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.Circ Heart Fail2013https://conductscience.org/library/papers/23861485PubMed

See all 91 referencesDownload CSV of references

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
42977703Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE-AHF).Clin Pharmacol Ther2026https://conductscience.org/library/papers/42977703PubMed
42814168SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications.Mol Biomed2026https://conductscience.org/library/papers/42814168PubMed
42784236Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection.Pathophysiology2026https://conductscience.org/library/papers/42784236PubMed
42782470Roles of inflammation and metabolic dysfunction in cardiovascular diseases: molecular mechanisms and therapeutic targets.Mol Biomed2026https://conductscience.org/library/papers/42782470PubMed
42694613An Integrated Therapeutic Strategy for Cardiorenal Syndrome to Target Oxidative Stress, Inflammation, and Fibrosis.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42694613PubMed
42638832Metabolic remodeling and cardiac functional adaptation mediated by dapagliflozin in patients with acute heart failure: a retrospective cohort study.Front Pharmacol2026https://conductscience.org/library/papers/42638832PubMed
42591312Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition.Front Mol Biosci2026https://conductscience.org/library/papers/42591312PubMed
42559753Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study.Diabetes Obes Metab2026https://conductscience.org/library/papers/42559753PubMed
42512119Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice.Biomedicines2026https://conductscience.org/library/papers/42512119PubMed
42491566Decoding cardiorenal crosstalk: Intercellular communication mechanisms and therapeutic insights in cardiorenal syndrome.iScience2026https://conductscience.org/library/papers/42491566PubMed
42395554Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices.bioRxiv2026https://conductscience.org/library/papers/42395554PubMed
42306580Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review.Int J Gen Med2026https://conductscience.org/library/papers/42306580PubMed
42302383Metabolic and redox pathway dysregulation in HIV-associated coronary endothelial dysfunction.Am J Physiol Heart Circ Physiol2026https://conductscience.org/library/papers/42302383PubMed
42199956Randomized Controlled Trial of Dapagliflozin for Post-Transplant Diabetes Mellitus in Renal Transplant Recipients.Kidney Int Rep2026https://conductscience.org/library/papers/42199956PubMed
42146022Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria.Front Physiol2026https://conductscience.org/library/papers/42146022PubMed
42110178Mechanisms and Therapeutic Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42110178PubMed
42108503Electrostatic lipidopathy drives human diabetic heart failure.Cardiovasc Diabetol Endocrinol Rep2026https://conductscience.org/library/papers/42108503PubMed
42086691Target trial emulation of sodium glucose cotransporter 2 inhibitors and clinical outcomes in diabetes and end stage kidney disease.Sci Rep2026https://conductscience.org/library/papers/42086691PubMed
42053960Dapagliflozin mitigates acute pancreatitis induced by L-arginine in Rats through modulation of TLR-4/NF-κB/NLRP3 pathway: integrated biochemical, histopathological, and in silico study.Inflammopharmacology2026https://conductscience.org/library/papers/42053960PubMed
42038319Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome.Front Pharmacol2026https://conductscience.org/library/papers/42038319PubMed

See all 36 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39680452

GET https://conductscience.org/api/papers/v1/39680452/authors?page=2